奈达铂同步化疗对中晚期宫颈癌患者uPA、VEGF及Ki-67表达的影响

目的 探讨奈达铂同步化疗对中晚期宫颈癌患者uPA、VEGF及Ki-67表达的影响.方法 收治的80例原发性宫颈癌患者随机分为观察组和对照组,每组40例.观察组采用奈达铂同步化疗治疗,对照组采用单纯放疗治疗,比较2组患者治疗效果及治疗前后uPA、VEGF和Ki-67表达阳性率变化.结果 观察组治疗总有效率为95骀.0%显著高于对照组的80.0%(P<0.05);随访期2组患者生存率、复发率和远处转移率差异有统计学意义(P<0.05);宫颈癌患者癌变组织中uPA、VEGF和Ki-67表达阳性率显著高于正常宫颈组织,差异有统计学意义(P<0.05);2组患者治疗后uPA、VEGF和Ki-67表达阳性率显著下降(P<0.05),且观察组下降程度显著高于对照组(P<0.05);观察组患者奈达铂同步化疗Ki-67阳性组化疗有效率显著高于阴性组,差异有统计学意义(P<0.05);观察组与对照组不良反应率比较差异无统计学意义(P>0.05).结论 奈达铂同步化疗能够显著降低中晚期宫颈癌患者宫颈组织中uPA、VEGF和Ki-67表达阳性率,提高中晚期宫颈癌患者治疗疗效,且患者能够耐受相关不良反应,值得临床推广使用.

Efffects of nedaplatin concurrent chemotherapy on the expression levels of uPA,VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage

Objective To observe the efffects of nedaplatin concurrent chemotherapy on the expression levels of uPA , VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage .Methods Eighty patients with primary cervical cancer who were admitted and treated in our hospital from March 2011 to March 2012 were randomly divided into observation group ( n =40 ) and control group ( n =40 ) .The patients in observation group were treated by nedaplatin concurrent chemotherapy ,however ,the patients in control group were treated by radiotherapy only .The therapeutic effects and positive expression rates of uPA ,VEGF and Ki-67 before and after treatment were observed and compared between two groups . Results The total effective rate in observation group was 95.0%,which was significantly higher than that (80.0%) in control group ( P <0.05).During follow -up there were significant differences in survival rate ,relapse rate and distant metastasis rate between two groups ( P <0.05).The positive expression rates of uPA ,VEGF and Ki-67 in cancerous tissues of patients with cervical cancer were significantly higher than those in normal cervical tissues ( P <0.05).The positive expression rates of uPA,VEGF and Ki-67 were obviously decreased after treatment in both groups ( P <0.05),moreover,the decrease degree in onservation group was more obvious than that in control group ( P <0.05).The effective rates in observation group with positive Ki-67 were significantly higher than those in observation group with negative Ki-67 ( P <0.05).However there were no significant differences in the incidence rates of adverse reactions between two groups ( P >0.05).Conclusion The nedaplatin concurrent chemotherapy can obviously decrease the positive expression rates of uPA , VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage and can enhance therapeutic effect ,without obvious adverse reactions ,thus,which is worth using widely in clinical practice .